Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Primary Objectives
1. To evaluate the Response Rate (RR) for amrubicin in patients with metastatic or advanced
sarcoma as first line therapy.
2. To evaluate Progression Free Survival (PFS).
Secondary Objectives
1. To assess the safety and tolerability of amrubicin in this patient population.
2. To evaluate whether certain histologic subtypes of sarcoma demonstrate a differential
response to amrubicin.
3. To investigate quality of response with radiographic evaluation using both Response
Evaluation Criteria In Solid Tumors (RECIST) and Choi criteria.
4. To evaluate overall survival (OS).